DIANT licenses continuous manufacturing tech

By The Science Advisory Board staff writers

November 13, 2020 -- The University of Connecticut has licensed its continuous manufacturing technology for pharmaceutical nanoparticles to DIANT Pharma.

The platform is a continuous manufacturing system for nanoparticle drug delivery systems. It is specifically designed for liposomal formulations but can work with a range of nanoparticles such as lipid nanoparticles, polymeric micelles, and emulsions. The system offers high control over particle size, high throughput, and a small footprint.

The technology was developed by Antonio Costa and Diane Burgess of the university with more than $5 million in funding from the U.S. Food and Drug Administration. Burgess and Costa formed DIANT Pharma in 2019.

The technology is ready to work in good manufacturing practice facilities, according to DIANT.

Sanofi's continuous manufacturing facility wins award
Sanofi has won the International Society for Pharmaceutical Engineering Overall Facility of the Year Award for its digitally enabled continuous biomanufacturing...
Faster fluid mixing could reduce costs for silica microparticles
A surprisingly simple approach to manufacturing silica nanoparticles by taking advantage of fluid dynamics in tiny Teflon tubes could reduce manufacturing...
NIIMBL funds new biopharmaceutical manufacturing projects
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that it is funding 14 new projects in technology, workforce...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter